Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors.
The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -2.01 Increased by +43.65% | -1.96 Decreased by -2.68% |
| Nov 13, 24 | -1.87 | -1.96 Increased by +4.59% |
| Aug 13, 24 | -1.86 | -1.90 Increased by +2.11% |
| May 14, 24 | -1.84 | -2.66 Increased by +30.83% |
| Mar 26, 24 | -3.57 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -34.27 M Increased by +42.43% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -31.76 M Increased by +38.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -31.56 M Increased by +39.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -30.92 M Increased by +33.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.62 M Increased by +N/A% | -59.54 M Decreased by -1.24% | Decreased by -2.27 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -51.28 M Decreased by -1.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 - | -52.31 M - | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -46.47 M - | Decreased by N/A% - |